ADXS (Ayala Pharmaceuticals) Total Assets : $16.58 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ayala Pharmaceuticals Total Assets?

Ayala Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $16.58 Mil.

Total Assets is connected with ROA %. Ayala Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -837.79%. Total Assets is also linked to Revenue through Asset Turnover. Ayala Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Ayala Pharmaceuticals Total Assets Historical Data

The historical data trend for Ayala Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ayala Pharmaceuticals Total Assets Chart

Ayala Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

20.05

45.83

41.13

7.77

16.58

Ayala Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															14.26	7.77	12.15	6.98	16.58

Ayala Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Ayala Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-24.417	+	40.996
	=	16.58

Ayala Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-24.417	+	40.996
	=	16.58

Ayala Pharmaceuticals (OTCPK:ADXS) Total Assets Explanation

Total Assets is connected with ROA %.

Ayala Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-98.692	/	( (6.981	+	16.579)	/ 2 )
	=	-98.692	/	11.78
	=	-837.79 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Ayala Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (6.981	+	16.579)	/ 2 )
=	0	/	11.78
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Ayala Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Ayala Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Ayala Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ayala Pharmaceuticals Inc (OTCPK:ADXS) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 08852

Website

https://www.ayalapharma.com

Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.

Executives

Yair Chaim Schindel	other: shareholder of 10% holder	YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
Roni Mamluk	director, officer: CEO	CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
Gary B. Gordon	officer: Chief Medical Officer	C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Vered Bisker-leib	director	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Harel Insurance Co Ltd	10 percent owner	ABBA HILLEL 3, RAMAT GAN L3 5211802
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Murray A Goldberg	director	2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Maimon Yossi	officer: CFO	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Harel Insurance Investments & Financial Services Ltd.	10 percent owner	HAREL HOUSE, 3 ABBA HILLEL ST., RAMAT GAN L3 52118
Todd Sone	director	C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104